Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cangene To Acquire Hemophilia Assets | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cangene To Acquire Hemophilia Assets

Will gain IB1001 and other assets from Ipsen, Inspiration

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cangene Corp. has entered an agreement to acquire investigational hemophilia compound IB1001 and certain other assets from Ipsen and Inspiration Biopharmaceuticals, in connection with Inspiration’s bankruptcy proceedings. The transaction is expected to close mid-February and is subject to bankruptcy court approval and customary closing conditions. Cangene will pay approximately $5.9 million upfront, as well as royalties on sales and additional payments for certain sales milestones.
 
IB1001 is an intravenous recombinant Factor IX (rFIX) being developed for the treatment and prevention of bleeding episodes in hemophilia B. The IB1001 development program includes pharmacokinetic, safety, and efficacy data from a Phase III trial in people with hemophilia B. A BLA and MAA for IB1001 are under review by the FDA and the EMA, respectively. 
 
John A. Sedor, president and chief executive officer of Cangene, said, “The acquisition of IB1001 is consistent with our strategy of targeting late-stage products to drive growth in our commercial business. We are a patient-focused company and the addition of IB1001 to our pipeline provides an opportunity to address a significant global need for patients with hemophilia B. We will use our significant experience in developing and commercializing biological products to resolve the regulatory challenges and bring value to hemophilia B patients and to Cangene.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics